Evidence map›Paper›PMID 30607479›Full record

ArticlePsychopharmacology2019

Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.

Ajeesh Koshy Cherian, Aaron Kucinski, Ryan Wu, Inge E M de Jong, Martin Sarter

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.Movement disorders : official journal of the Movement Disorder Society · 2021
    Review
  7. Complex Movement Control in a Rat Model of Parkinsonian Falls: Bidirectional Control by Striatal Cholinergic Interneurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2020
    Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Ajeesh Koshy CherianDepartment of Psychology, University of Michigan, 530 Church Street, Ann Arbor, MI, 48109, USA.
Aaron KucinskiDepartment of Psychology, University of Michigan, 530 Church Street, Ann Arbor, MI, 48109, USA.
Ryan WuDepartment of Psychology, University of Michigan, 530 Church Street, Ann Arbor, MI, 48109, USA.
Inge E M de JongDivision of Neurodegeneration, H. Lundbeck A/S, Valby, Denmark.
Martin SarterDepartment of Psychology, University of Michigan, 530 Church Street, Ann Arbor, MI, 48109, USA. msarter@umich.edu.ORCID http://orcid.org/0000-0003-0441-9936
University of Michigan · USLundbeck (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleFalls in patients with Parkinson's disease (PD) are associated with cognitive, specifically attentional impairments and with losses in cholinergic projection systems. We previously established an animal model of the combined basal forebrain cholinergic-striatal dopaminergic losses of PD fallers (Dual Lesioned, DL, rats) and demonstrated that treating DL rats with an acetylcholinesterase inhibitor (AChEI), donepezil, together with a 5HT

objectivesHere, we employed a longer and more taxing rotating beam apparatus to determine the potential therapeutic efficacy of idalopirdine when combined with the pseudo-irreversible, and thus relatively long-acting, AChE- and butyrylcholinesterase- (BuChE) inhibitor rivastigmine.

resultsAs before, vehicle-treated DL rats fell more frequently, committed more slips, and exhibited more movement stoppages than intact control rats. Repeated intermittent administration of rivastigmine and idalopirdine significantly improved the performance of DL rats. Rivastigmine alone also produced strong trends for reducing falls and slips. The combination treatment was more effective than rivastigmine alone in reducing stoppages and stoppage-associated falls. As before, idalopirdine treatment alone was ineffective.

conclusionsThese results extend the prediction that the combined treatment with idalopirdine and an AChEI improves complex movement control and reduces the propensity for falls in patients with movement disorders. Because of the importance of finding better treatments for gait and balance deficits in PD, the present results may further motivate a clinical exploration of the usefulness of this combination treatment.

Indexed as

Accidental FallsAnimalsBasal ForebrainBenzylaminesCholinesterase InhibitorsCognitive DysfunctionCorpus StriatumDisease Models, AnimalDrug Therapy, CombinationFemaleFluorocarbonsIndolesMaleParkinson DiseaseRatsRats, Sprague-Dawley(2-(6-fluoro-1H-indol-3-yl)-ethyl)-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)amineBenzylaminesCholinesterase InhibitorsFluorocarbonsIndolesRivastigmineSerotonin AntagonistsAcetylcholineBasal gangliaDopamineFallsIdalopirdineParkinson’s diseaseRivastigmine

Identifiers

PMID30607479
OpenAlexW2907016040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.